IP Library Granted Patent US 10,376,564
Granted Patent B2
US 10,376,564 · App. 15/124,734 · Granted Aug 13, 2019

Interleukin-2 for treating food allergy

Inventors: David Klatzmann (Paris, FR); Bertrand Bellier (Paris, FR)
Assignees: SORBONNE UNIVERSITE; ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
A61K38/2013A61K9/0053A61K38/20A61K39/35A61K2039/542A61K2039/55533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,564
App. No.
15/124,734
Granted
Aug 13, 2019
Kind
B2
Abstract

The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol in combination with a food allergen.

Claims (19)

1. A method for treating a food allergy in a subject comprising administering Interleukin-2 (IL-2) to said subject, wherein IL-2 is administered: (i) subcutaneously at a dosage of less than 5 MIU/day, (ii) orally at a dosage of between 0.5 and 10 MIU/day or (iii) intranasally at a dosage of between 0.5 and 5 MIU/day.

2. The method of claim 1 , wherein the subject is afflicted with a food allergy selected from the group consisting of peanut allergy, milk allergy, nut allergy, corn allergy, fruit allergy, garlic allergy, oat allergy, shellfish allergy, soy allergy, wheat allergy, egg allergy, sesame allergy, olive oil allergy, cheese allergy, crustacean allergy, and fish allergy.

3. The method of claim 2 , wherein the wheat allergy is gluten allergy.

4. The method of claim 1 , wherein IL-2 is administered repeatedly.

5. The method of claim 1 , wherein IL-2 is administered during a cyclic period that lasts from about 1 month to about one year, said cyclic period being optionally repeated every two or three years.

6. The method of claim 1 , wherein said method reduces the risk, severity or occurrence of an allergic response or crisis.

7. The method of claim 1 , wherein IL-2 is administered in combination with a food allergen.

8. The method of claim 2 , wherein the subject is afflicted with an egg allergy.

9. The method of claim 1 , wherein IL-2 is administered subcutaneously at a dosage of less than 5 MIU/day.

10. The method of claim 9 , wherein IL-2 is administered subcutaneously at a dosage of less than 3.5 MIU/day.

11. The method of claim 10 , wherein IL-2 is administered subcutaneously at a dosage of between 0.05 MIU and 2 MIU/day or between 0.1 and 3 MIU/day.

12. The method of claim 1 , wherein IL-2 is administered orally at a dosage of between 0.5 and 10 MIU/day.

13. The method of claim 12 , wherein IL-2 is administered orally at a dosage of between 1 and 5 MIU/day.

14. The method of claim 12 , wherein IL-2 is administered orally at a dosage of between 5 and 10 MIU/day.

15. The method of claim 1 , wherein IL-2 is administered intranasally at a dosage of between 0.5 and 5 MIU/day.

16. The method of claim 15 , wherein IL-2 is administered intranasally at a dosage of between 1 and 5 MIU/day.

17. A method for treating a food allergy in a subject comprising administering Interleukin-2 (IL-2) to said subject, wherein IL-2 is administered subcutaneously, orally or intranasally at a dosage of 0.05 to 10 MIU/m 2 /day.

18. The method according to claim 1 , wherein IL-2 is aldesleukin.

19. The method according to claim 17 , wherein IL-2 is aldesleukin.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Aug 24, 2018
From: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); SORBONNE UNIVERSITE
To: SORBONNE UNIVERSITE
Reel/Frame 046691/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2016
From: KLATZMANN, DAVID; BELLIER, BERTRAND
To: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 040040/0784 →
Priority Claims (1)
EP 14305348 · Mar 11, 2014 · regional
Continuity (1)
Related Publication 20170020962A1 · Jan 26, 2017
Cited By (1)
US 50,550